2008 ASCO Genitourinary Cancers Symposium: Updates in the Management of Prostate and Kidney Cancers - CME
C. Dean Buckner, MD

ASCO 2007: Update on the Management of Genitourinary Malignancies
Nancy A. Dawson, MD – Lombardi Comprehensive Cancer Center

Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease (11/19/2009)
Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.

Physical Activity May Reduce Risk of Developing Prostate Cancer (11/18/2009)
Researchers from U.S. and European medical centers have reported that not sitting during work, occupational activity, walking, and biking can reduce the risk of developing prostate cancer. The details of this study were published early online on October 27, 2009 in the British Journal of Cancer.

High-dose Mixed Proton and Photon Radiotherapy May Improve Treatment of Prostate Cancer (11/13/2009)
Researchers affiliated with the Proton Radiation Oncology Group (PROG)/American College of Radiology (ACR) 95-09 study have reported that mixed proton and photon radiotherapy improves outcomes of patients with low- and intermediate-risk prostate cancer. The details of this randomized trial were presented at the 2009 meeting of the American Society of Radiation Therapy and Oncology (ASTRO) in the first week of November.

Radiotherapy and Hormonal Therapy Effective for Men with Prostate Cancer Failing Surgery (11/10/2009)
Researchers from the Mayo Clinic have reported that relapse-free survival was over 90% in patients treated with salvage radiotherapy (RT) plus two years of androgen deprivation therapy (ADT) for post-prostatectomy relapse. The details of this study were presented at the 2009 meeting of the American Society of Therapeutic Radiology and Oncology in the first week in November, 2009.

Neoadjuvant Taxotere® and ADT Well Tolerated in High-risk Prostate Cancer (10/27/2009)
Researchers from Spain have reported that neoadjuvant Taxotere® (docetaxel) and androgen deprivation therapy (ADT) was well tolerated and associated with a 6% pathological complete response (pCR) rate and a 6% near pCR rate in men with high-risk prostate cancer. The details of this study appeared in the October 13, 2009 issue of the British Journal of Cancer.